Chief Scientific Officer - Early Drug Development

The Chief Scientific Officer - Early Drug Development will formulate and lead the company's global early-stage R&D strategy, establishing the R&D roadmap from target validation to proof-of-concept (POC).

Responsibilities

• Lead the drug chemistry team and the biology team.
• Establish a global R&D layout and talent echelon for innovative drugs of Qilu.
• Plan and make decisions regarding the innovative drug pipeline, including cutting-edge technology fields such as small molecules, large molecules, ADCs, and small nucleic acids.
• Establish strategic partnerships with the global academic community, research institutions, and biotechnology companies to introduce cutting‑edge technologies.
• Research on leadership mechanisms and formulate biomarker strategies to provide a solid scientific basis for R&D decisions.

Qualifications

• Possess a doctoral degree in life sciences or a related medical field.
• Over 20 years of research and development experience in multinational pharmaceutical companies or top biotech firms.

Required Skills

• Profound biological knowledge in core disease areas such as oncology, metabolism, autoimmunity, or the central nervous system.
• Deep understanding of emerging therapeutic modalities.
• Complete R&D success experience from the laboratory to the clinic.
• Led and advanced at least five innovative drug projects into the clinical stage and successfully completed POC.
• Outstanding scientific insight and strategic decision‑making ability to predict industry trends and transform them into the company's R&D advantages.
• Outstanding leadership with the charisma and influence to inspire, attract, and retain top scientific talents.

Preferred Skills

• Experience in establishing and managing global R&D teams.
• Strong network within the academic and biotechnology communities.

Pay range and compensation package

Competitive salary and comprehensive benefits package commensurate with experience.